Gratsinna A. Martirosyan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gratsinna A. Martirosyan has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Abu M. Sulaev
Department of Endocrinology №1 of Sklifosovsky Institute of Clinical Medicine (Endocrinology Department of Sechenov University), First Moscow State Medical University (Sechenov University), Moscow
1 shared publication - Anna S. Arustamyan
National Medical Endocrinology Research Centre named after Academician I. I. Dedov
1 shared publication - Elena Viktorovna Surkova
Sechenov First Moscow State Medical University (Sechenov University)
1 shared publication - Ilya I. Amergoolov
Sechenov First Moscow State Medical University (Sechenov University)
1 shared publication - Maria G. Pavlova
Sechenov First Moscow State Medical University (Sechenov University)
1 shared publication - Marina Kalashnikova
Basque Center on Cognition, Brain and Language, San Sebastian, Spain
1 shared publication
Latest Publications
- Open Access
- 30 October 2024
- Published by PAGEPress Publications in European Journal of Translational Myology
- Vol. 34 (1)
Endocrine disorders in Kearns-Sayre syndrome with different severity of symptoms: two case reports and a literature review
Kearns-Sayre Syndrome (KSS) is a variant of mitochondrial disorder caused by a Mitochondrial Deoxyribonucleic Acid (mtDNA) deletion. Clinical manifestations of KSS can include different organ and system involvement. Different organ malfunctions, more often cardiac dysfunction, can lead to death. No effective treatment of this condition exists to date. Here, we report two patients with KSS. Female patient with a large-scale deletion of 7,020 base pairs (bp) suffered from hypogonadism, diabetes mellitus with fluctuating glucose levels, and had poor general health. A male patient with a common 4,977 bp deletion did not have diabetes mellitus but had impaired glucose tolerance. He also had a higher level of general health than our female patient. Both patients had reduced Bone Mineral Density (BMD). In female patients, calcium and vitamin D supplementation combined with metabolic therapy and nutritional drink supplements helped increase BMD (up to 32% in L1-L4). Comparing these two patients suggests that the larger the mtDNA deletion is, the more severe the course of the disease is. Not only does the size of the mtDNA deletion probably determine the severity of the disease, but also such factors as mtDNA heteroplasmy level, presence of mtDNA duplications, and pleioplasmy. Moreover, continuous nonconsecutive metabolic therapy and nutritional supplements are helpful in the prevention of deterioration of symptoms and general health.
- 30 October 2024
- Published by PAGEPress Publications in European Journal of Translational Myology
- Vol. 34 (1)
Open AccessEndocrine disorders in Kearns-Sayre syndrome with different severity of symptoms: two case reports and a literature review
Kearns-Sayre Syndrome (KSS) is a variant of mitochondrial disorder caused by a Mitochondrial Deoxyribonucleic Acid (mtDNA) deletion. Clinical manifestations of KSS can include different organ and system involvement. Different organ malfunctions, more often cardiac dysfunction, can lead to death. No effective treatment of this condition exists to date. Here, we report two patients with KSS. Female patient with a large-scale deletion of 7,020 base pairs (bp) suffered from hypogonadism, diabetes mellitus with fluctuating glucose levels, and had poor general health. A male patient with a common 4,977 bp deletion did not have diabetes mellitus but had impaired glucose tolerance. He also had a higher level of general health than our female patient. Both patients had reduced Bone Mineral Density (BMD). In female patients, calcium and vitamin D supplementation combined with metabolic therapy and nutritional drink supplements helped increase BMD (up to 32% in L1-L4). Comparing these two patients suggests that the larger the mtDNA deletion is, the more severe the course of the disease is. Not only does the size of the mtDNA deletion probably determine the severity of the disease, but also such factors as mtDNA heteroplasmy level, presence of mtDNA duplications, and pleioplasmy. Moreover, continuous nonconsecutive metabolic therapy and nutritional supplements are helpful in the prevention of deterioration of symptoms and general health.